A pioneering clinical study has revealed that providing pluripotent cells to unborn babies affected by spina bifida as part of a surgical repair could constitute a "major milestone" in addressing congenital conditions.
Study Parameters and Security
The US-based trial examined six developing infants with myelomeningocele. Medical teams placed placenta-derived mesenchymal stem cells on the exposed area of the developing neural column while the defect was being closed.
Importantly, the stem cell application proved to be secure. The study team reported that the treatment did not lead to tumors, interfere with wound healing, or prevent the reversal of co-occurring hindbrain herniation.
Positive Developments
Post-birth MRI scans showed a full resolution of brainstem displacement in every participant. This neurological improvement is a key indicator for enhanced physical outcomes.
"In the event it allows more children to achieve ambulation who otherwise would not, it may emerge as their standard of care," commented the principal investigator. "These findings are extremely promising and open the door to a variety of prospective innovative interventions."
Broader Impact and Encouragement
Experts not involved in the trial proposed that subsequent studies of these observed advantages could announce a "new era" in in-utero treatment. The potential to improve nerve function impairment seen in utero is regarded as a transformative goal.
Especially significant would be advancements for bladder and bowel function, which are typical difficulties for those diagnosed with this defect.
Looking Ahead
Despite this being a first-in-human effort focused on a handful of cases, its safety demonstration and positive signals provide a strong foundation for expanded clinical research. The addition of cellular treatment with current in-utero repair procedures presents significant potential for improving the prognosis for infants diagnosed prenatally with myelomeningocele.